Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Aims</h3><p>Fibroblast growth factor 1 (FGF1) demonstrated protection against nonalcoholic fatty liver disease (NAFLD) in type 2 diabetic and obese mice by an uncertain mechanism. This study investigated the therapeutic activity and mechanism of a non‐mitogenic FGF1 variant (FGF1<sup>△HBS</sup>) against NAFLD. </p><p>Approach and Results</p><p>FGF1<sup>△HBS</sup> administration was effective in 9‐month old <i>db/db</i> mice with NAFLD; liver weight, lipid deposition and inflammation declined and liver injury decreased. FGF1<sup>△HBS</sup> reduced oxidative stress by stimulating nuclear translocation of nuclear factor erythroid 2‐related factor 2 (Nrf2) and elevation of antioxidant protein expression. FGF1<sup>△HBS</sup> also inhibited activity and/or expression of lipogenic genes, coincident with phosphorylation of AMP‐activated protein kinase (AMPK) and its substrates. Mechanistic studies on palmitate exposed hepatic cells demonstrated that NAFLD‐like oxidative damage and lipid accumulation could be reversed by FGF1<sup>△HBS</sup>. In palmitate‐treated hepatic cells, siRNA knockdown of Nrf2 abolished only FGF1<sup>△HBS</sup> anti‐oxidative actions but not improvement of lipid metabolism. In contrast, AMPK inhibition by pharmacological agent or siRNA abolished FGF1<sup>△HBS</sup> benefits on both oxidative stress and lipid metabolism that were FGF receptor 4 (FGFR4) dependent. Further support of these <i>in vitro</i> findings is that liver‐specific AMPK knockout abolished therapeutic effects of FGF1<sup>△HBS</sup> against high‐fat/high‐sugar diet‐induced hepatic steatosis. Moreover, FGF1<sup>△HBS</sup> improved high‐fat/high‐cholesterol diet‐induced steatohepatitis and fibrosis in apolipoprotein E knockout mice. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>These findings indicate that FGF1<sup>△HBS</sup> is effective for preventing and reversing liver steatosis and steatohepatitis and acts by activation of AMPK via hepatocyte FGFR4. </p></section>

Acid Fibroblast Growth Factor Facilitates the Progression of Atherosclerotic Plaques Regardless of Alterations in Serum Lipid Expression Levels in HFD‑fed ApoE‑/‑ Mice.

Folic Acid Delays Development of Atherosclerosis in Low‐density Lipoprotein Receptor‐deficient Mice

Possible Role of Fibroblast Growth Factor 21 on Atherosclerosis Via Amelioration of Endoplasmic Reticulum Stress-Mediated Apoptosis in Apoe−/− Mice

Therapeutic Effects of Fibroblast Growth Factor‑21 Against Atherosclerosis Via the NF‑κB Pathway.

Fgf23 expression increases atherosclerotic plaque burden in male ApoE deficient mice

Macrophage-derived FGFR1 drives atherosclerosis through PLCγ-mediated activation of NF-κB inflammatory signaling pathway

Pharmacological treatment with FGF21 strongly improves plasma cholesterol metabolism to reduce atherosclerosis

Macrophage-derived FGFR1 Drives Atherosclerosis Through PLCγ-mediated Activation of NF-κB Inflammatory Signalling Pathway.

Adventitial Fibroblasts Are Activated In The Early Stages Of Atherosclerosis In The Apolipoprotein E Knockout Mouse

Ferulic Acid Ameliorates Atherosclerotic Injury by Modulating Gut Microbiota and Lipid Metabolism

Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress

Lactoferrin Alleviates the Progression of Atherosclerosis in ApoE-/- Mice Fed with High-Fat/Cholesterol Diet Through Cholesterol Homeostasis.

Activating Adenosine Monophosphate–Activated Protein Kinase Mediates Fibroblast Growth Factor 1 Protection From Nonalcoholic Fatty Liver Disease in Mice

Fibroblast growth factor 21 regulates foam cells formation and inflammatory response in Ox-LDL-induced THP-1 macrophages

Ferulic Acid Alleviates Atherosclerotic Plaques by Inhibiting VSMC Proliferation Through the NO/p21 Signaling pathway

Angiopoietin-like protein 8 accelerates atherosclerosis in ApoE−/− mice

Suppressing the intestinal farnesoid X receptor/sphingomyelin phosphodiesterase 3 axis decreases atherosclerosis

The research advance of fibroblast growth factor 21 in anti-atherosclerosis

Myriocin and D-PDMP Ameliorate Atherosclerosis in ApoE &Lt;sup>-/-</sup> Mice Via Reducing Lipid Uptake and Vascular Inflammation

FGF21 induces autophagy‐mediated cholesterol efflux to inhibit atherogenesis via RACK1 up‐regulation

Dietary α-Linolenic Acid-Rich Flaxseed Oil Ameliorates High-Fat Diet-Induced Atherosclerosis via Gut Microbiota-Inflammation-Artery Axis in ApoE−/− Mice